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Abstract
Background: The U.S. Food and Drug Administration (FDA) recently linked antiepileptic drug (AED) exposure to 
suicide-related behaviors based on meta-analysis of randomized clinical trials. We examined the relationship between 
suicide-related behaviors and different AEDs in older veterans receiving new AED monotherapy from the Veterans 
Health Administration (VA), controlling for potential confounders.
Methods: VA and Medicare databases were used to identify veterans 66 years and older, who received a) care from the 
VA between 1999 and 2004, and b) an incident AED (monotherapy) prescription. Previously validated ICD-9-CM codes 
were used to identify suicidal ideation or behavior (suicide-related behaviors cases), epilepsy, and other conditions 
previously associated with suicide-related behaviors. Each case was matched to controls based on prior history of 
suicide-related behaviors, year of AED prescription, and epilepsy status.
Results: The strongest predictor of suicide-related behaviors (N = 64; Controls N = 768) based on conditional logistic 
regression analysis was affective disorder (depression, anxiety, or post-traumatic stress disorder (PTSD); Odds Ratio 4.42, 
95% CI 2.30 to 8.49) diagnosed before AED treatment. Increased suicide-related behaviors were not associated with 
individual AEDs, including the most commonly prescribed AED in the US - phenytoin.
Conclusion: Our extensive diagnostic and treatment data demonstrated that the strongest predictor of suicide-related 
behaviors for older patients newly treated with AED monotherapy was a previous diagnosis of affective disorder. 
Additional, research using a larger sample is needed to clearly determine the risk of suicide-related behaviors among 
less commonly used AEDs.
Background
At the end of January 2008, the FDA issued an alert indicat-
ing that antiepileptic drug (AED) treatment is associated
with increased risk for suicidal ideation, attempt and com-
pletion. This decision was based on a meta-analysis of sui-
cidal ideation and behavior in placebo-controlled clinical
studies of 11 antiepileptic drugs used in the treatment of
epilepsy, psychiatric disorders and other conditions (includ-
ing migraine and neuropathic pain) [1]. A higher percent-
age (0.43%) of patients receiving an AED had suicidal
behavior and ideation compared to patients in placebo
groups (0.22%). In addition, the relative risk for suicide-
related behaviors was found to be highest in patients being
treated for epilepsy compared to those being treated with
AEDs for other medical conditions. No differences in risk
were found among the 11 AEDs studied. The FDA recom-
mended that healthcare professionals should closely moni-
tor all patients who are currently taking or starting any AED
for behavioral changes. Healthcare providers were
instructed to inform patients, their families, and caregivers
of the potential for an increase in the risk of suicide-related
behaviors. The FDA also advised providers to balance the
clinical need for these medications with the elevated risk
for suicide-related behaviors.
Recent concern has been raised regarding the ability to
make appropriate recommendations regarding AEDs in
what has been termed a data poor environment [2]. Avorn
[2] suggested that the AED-suicide-related behaviors con-
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randomized clinical trials (RCT) designed specifically to
meet the requirements for FDA approval. Several limita-
tions of the FDA analysis suggest that additional research is
needed to better understand and interpret the findings
before definitively concluding that all AEDs increase risk
for suicidal behavior and ideation in all age groups.
Not only did the FDA analysis exclude the most com-
monly prescribed AED (phenytoin) used to treat epilepsy in
the US, but many of the individuals in the exposed groups
were on multiple AEDs, a factor recognized to increase risk
of suicide-related behaviors [3]. Moreover, the extent to
which RCT study participants reflect patients in clinical
practice is not clear because study inclusion and exclusion
criteria are variable and are not always available for ana-
lytic purposes. Based on assessments of previous clinical
trials [4], it is unlikely that RCT patients represent those
seen in clinical practice, especially with regard to older
adults, because enrollment is frequently limited with
respect to age, co-morbid conditions, and disease severity.
The goal of this study was to assess variation in suicide-
related behaviors, as defined by Silverman et al [5], in a
population not well represented by the data used for the
FDA analysis--individuals 66 years and older with new
exposure to AEDs-using data from the largest integrated
health care system in the United States, the Department of
Veterans Affairs, Veterans Health Administration (VA). As
older individuals are: 1) at greater risk for a number of con-
ditions for which these drugs are used (for example, epi-
lepsy, depression, chronic pain), [6-8] 2) are under-
represented in RCTs, 3) are more likely to be treated with
older AEDs not used in RCTs [9] and 4) face an increased
risk of suicide-related behaviors [10-12]. Our ability to con-
trol for concomitant psychiatric conditions provides impor-
tant insight into the relationship between AED exposure
and suicide-related behaviors.
Methods
We used national VA pharmacy, administrative, and Medi-
care data to identify cases and controls for this study. Cases
and controls were selected from the population of VA
patients 66 years and older who received care from the VA
between October 1, 1999 and September 30, 2004, and who
had VA pharmacy data available for at least one year prior
to the initial AED prescription. Individuals receiving a new
prescription for AED monotherapy without a previous AED
prescription were included in this analysis.
From the cohort of older VA patients who received a new
AED monotherapy during the study period, we identified
individuals with a diagnosis of suicidal behavior or ideation
(hereafter suicide-related behaviors) using ICD-9-CM
codes (V62.84 Suicidal ideation, 300.9 suicidal tendencies,
E9499, E950-E958, E962.0, E980-E989) for individuals
who remained on AEDs through the time of suicide attempt
or ideation. Those with any suicide attempt or ideation after
discontinuing AED were not considered in this study.
After identification of cases, we randomly matched the
maximal number of controls to each case (N = 12) to
increase power. Controls were matched to cases based on
history of suicide-related behaviors prior to AED prescrip-
tion, the year of first AED prescription, and diagnosis of
epilepsy.
Descriptions of epilepsy diagnosis and other measures
used in the conditional logistic regression model follow.
Because VA privacy rules preclude publication of data
where any cell has fewer than 11 individuals, we condensed
categories for a number of variables (described below) but
were still unable to report frequencies for gender or race
due to small numbers of women and non-white suicide-
related behaviors cases.
Epilepsy diagnosis was identified using an algorithm val-
idated for use with national VA and Medicare diagnostic
data in conjunction with VA pharmacy data [9]. Briefly, we
restricted the cohort to those with at least one year of VA
pharmacy and administrative data to assure a new diagnosis
of epilepsy (ICD-9-CM codes epilepsy (345.XX) or con-
vulsion (780.39) and a new prescription of an AED. Those
with a first diagnosis of epilepsy and a subsequent AED
within a year were identified as having new-onset epilepsy.
This algorithm was found to have positive predictive value
of 0.98.
Demographic Characteristics
Age, gender and race were obtained from VA data; Medi-
care data were used to supplement missing values. Since
older age has been associated with suicide-related behav-
iors [10] age was classified as 66 to 74, 75 years and older.
Race was classified as white and nonwhite because white
veterans have an increased risk of suicide-related behaviors
[11].
Other Clinical Characteristics
We included clinical characteristics that are associated with
use of AEDs and suicide-related behaviors in order to mini-
mize the potential for confounding by indication. If we
found a significant impact of an AED that is commonly
used for psychiatric conditions (for example, valproate,
lamotrigine) or chronic pain (for example, gabapentin), but
did not control for those conditions in the model, it is possi-
ble that the underlying condition being treated is the force
behind the significant relationship rather than medication
itself.
Prior psychiatric comorbidity
Individuals with a history of depression are consistently
found to be at increased risk for suicide, as are individuals
with other mental health conditions such as bipolar disorder
[12]. Because certain AEDs are more likely to be pre-
scribed for individuals with psychiatric comorbidity (for
example, valproate, carbamazepine, lamotrigine) [13], we
used ICD-9-CM codes to identify patients with a diagnosis
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300.09), post-traumatic stress disorder ((PTSD); 309.81),
bipolar disorder (296.0-296.1, 296.4-296.8), schizophrenia
(295.x [excluding 295.5]), substance abuse (291, 292, 303-
305 excluding 305.1) and other mental illness (290-312,
excluding the codes listed above). We combined depres-
sion, anxiety and PTSD as affective disorders, and schizo-
phrenia, other psychoses and bipolar disorder as serious
mental illness per Blow and colleagues [14]. Chi-square
analyses confirmed that relationships with suicide-related
behaviors were similar among these conditions. Indicator
variables for affective disorder, serious mental illness, sub-
stance abuse, and other mental illness were included in the
model to determine the unique contribution of each type of
psychiatric comorbidity.
Other physical conditions that may affect suicide-related
behaviors in older individuals include chronic pain, demen-
tia, and profound disease burden [12]. Chronic pain was
defined using ICD-9-CM codes for conditions identified as
being associated with persistent pain in the elderly by the
American Geriatrics Society which includes conditions
such as neuropathic pain [15]. Dementia was defined by
ICD-9-CM codes which have been validated in VA data-
bases [16]. Disease burden was quantified using a count of
chronic physical disease states defined by Selim's physical
comorbidity index (CI), developed for the veteran popula-
tion to assess disease burden. The physical CI counts 30
chronic physical conditions including stroke, hypertension,
diabetes, cardiovascular disease and peripheral vascular
disease [17]. As analyses using the continuous variable
were difficult to interpret, and no information appeared to
be lost, we used a median split to create low (0 to 6 condi-
tions) and high (≥ 7 conditions) comorbidity groups to aid
in interpretation.
Analysis
We provided descriptive statistics for cases and controls,
and bivariate analyses comparing the groups. Gabapentin
was selected as the comparator because patients with gaba-
pentin exposure comprised over 75% of the cohort, and no
other single AED was used by over 10% of the cohort. We
then analyzed the simultaneous effect of prognostic factors
of suicide-related behaviors using conditional logistic
regression (stratified by case/control status), implemented
via the SAS PHREG procedure (SAS 9.1, © 2002-2003
SAS Institute, Carey, NC, USA). The final model was
determined by performing a backward variable selection
procedure in which all the candidate variables described
above were included in the conditional logistic regression,
and then the least significant variables were removed one at
a time until only variables significant at P < 15 remained.
Results
Of the 449,269 individuals who received an AED between
FY 2000 and 2004, 114,333 had a new AED prescription.
Figure 1 demonstrates that of the 112,096 (7,445 with new-
onset epilepsy) who received AED monotherapy, 64 indi-
viduals had ICD-9-CM codes indicative of suicide-related
behaviors. Rates of suicide-related behaviors were not sig-
nificantly different for individuals with new-onset epilepsy
and those with other diagnoses (P = 0.38). After matching
12 controls to each case based on prior history of suicide-
related behaviors, epilepsy diagnosis and year of AED pre-
scription, the case-control sample consisted of 832 individ-
uals.
The sample was comprised primarily of men (97.5%, N =
811) and whites (86.4%, N = 719). Rates of suicide-related
behaviors did not differ by gender (P = 0.61) or race (P =
0.58). Approximately half of the sample was 66 to 74 years
of age (49.6%, N = 413), and there was no variation in sui-
cide-related behaviors by age (42.2% (66 to 74 years) vs.
57.8% (75 years and older), chi square = 1.59; P = 0.45).
This sample had high prevalence of chronic pain (85.7%, N
= 713) prior to AED prescription; 12% had diagnosed
dementia. The associations between suicide-related behav-
iors and chronic pain (P = 0.42) or chronic disease burden
(P = 0.14) were not statistically significant, but diagnosis of
dementia was significantly associated with suicide-relatedFlow chart of study design and cohort definitionigure 1 Flow chart of study design and cohort defi ition.
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tia; P < 0.01). Table 1 shows the prevalence of psychiatric
comorbidity groups. The bivariate relationship between
each psychiatric comorbidity group and suicide-related
behaviors was statistically significant (P < 0.01).
Most individuals in this sample received AED prescrip-
tions for gabapentin (76.8%; N = 639), followed by pheny-
toin (7.0%; N = 58), phenobarbital/primidone (6.6%; N =
55), valproate (5.9%; N = 49), and carbamazepine (3.1%, N
= 24). The remainder received levetiracetam or lamotrigine
(0.6%; N = 7). Because relationships with suicide-related
behaviors for these drugs were similar and numbers for
each drug were too low to examine individually, they were
combined for this analysis. The bivariate relationship
between type of AED and suicide-related behaviors was
statistically significant, with more cases observed for val-
proate and lamotrigine/levetiracetam than expected by
chance (P < 0.01). Conditional logistic regression models
using backward elimination resulted in only two variables
remaining in the final model: type of AED and affective
disorders. Table 2 shows results of the final model. A trend
for increased suicide-related behaviors among those pre-
scribed levetiracetam or lamotrigine (Odds Ratio 10.2 95%
CI 1.1 to 97.0) was found, but interpretation is difficult
since few patients received either drug, and groups were
combined in order to conduct the multivariable analysis.
Individuals with a diagnosis of affective disorder prior to
their prescription of AED were more likely to have subse-
quent suicide attempt or ideation than those without prior
affective disorder (OR 4.2, 95% confidence interval 2.4 to
7.5).
Discussion
There has been significant concern regarding the extent to
which findings from the FDA analysis of suicide-related
behaviors in patients with AED exposure generalize to all
patients receiving AEDs. Not all AEDs were included in
the FDA analysis, yet all AEDs were identified as having
increased risk of suicide-related behaviors. The assessment
of risk was ascertained using data not designed to examine
this risk, and using populations that are not necessarily sim-
ilar to those in clinical practice [2,18]. The focus of our
study allowed us to begin to address variation in risk for
suicide-related behaviors among older patients receiving
new AED monotherapy. Affective disorders are associated
with suicide-related behaviors, and certain AEDs are more
likely to be dispensed to persons with psychiatric comor-
bidities such as depression and bipolar disorder. An impor-
tant contribution of this study was to control for psychiatric
conditions that may be associated with suicide-related
behaviors, and which may have been the reason for the
AED prescription.
Our analysis found that the absolute risk of suicide-
related behaviors (0.06% (64/112,096)) was nearly 10-fold
lower that that observed in the FDA study (0.43% (120/
27,863)) in our study population. Although the majority of
veterans received gabapentin in our study, 13.6% (N = 113)
were treated with phenytoin or a barbiturate providing new
information about the older AEDs not possible in the FDA
analysis of recent RCT. Once psychiatric conditions and
potential confounding by indication were controlled, we
found that individuals receiving lamotrigine or levetirac-
etam were more likely to have suicide-related behaviors
diagnoses than individuals receiving gabapentin. Previous
work has linked specific AEDs, including levetiracetam, to
Table 1: Psychiatric comorbidity groups among older veterans on new AED monotherapy
Suicide-related behaviors Cases
N = 64
Controls
N = 768
Psychiatric Conditions N (%) N (%)
Affective Disorders#^ 44 (68.8) 265 (34.5)
Serious Mental Illness*# 19 (29.7) 119 (15.5)
Substance Abuse/Dependence^ 13 (20.3) 86 (11.2)
Other Mental Illness^ 25 (39.1) 151 (19.7)
# Depression, Anxiety, PTSD
*Schizophrenia, Other Psychoses, Bipolar Disorder
^P < .001
Psychiatric comorbidity categories are not mutually exclusive; some patients had more than one concomitant psychiatric diagnosis.
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found similar trends for lamotrigine and topiramate [1].
Given the small number of individuals with exposure to
lamotrigine or levetiracetam at the time of this study, our
study lacked power to identify true differences if they
existed among these patients. Additional research using a
longer study period and more patients on newer AEDs is
needed to fully address this question.
In older VA patients who were started on AED monother-
apy, the strongest reliable predictor for suicide-related
behaviors was the diagnosis of an affective disorder
(depression, anxiety, PTSD) prior to initiation of AED
treatment. Although a seemingly intuitive finding, the sig-
nificant effect of a prior affective disorder in our model is a
strong result given the comparatively small sample size.
Our finding linking affective disorder with suicide-related
behaviors is consistent with earlier studies that found that
affective illness, particularly depression, is the predominant
psychopathology associated with suicide-related behaviors
in later life [22,23]. While other psychiatric diagnoses,
including bipolar disorder and schizophrenia, were also
associated with suicide-related behaviors in bivariate analy-
ses, they were no longer significant after controlling for
affective disorders. This is likely due to the fact that 30% of
the sample had diagnoses for two or more psychiatric
comorbidity groups, and over 80% of those with multiple
psychiatric conditions were diagnosed with an affective dis-
order. Affective disorders are commonly associated with
epilepsy and individuals with epilepsy have been reported
to have a higher risk of suicide, even after controlling for
co-morbid psychiatric disease and sociodemographic fac-
tors [24-26].
Our study findings were also different than the FDA's
alert that reported that the relative risk for suicidality was
highest in patients being treated for epilepsy compared to
those being treated for other medical conditions. In our
findings the rates of suicidal behavior were not significantly
different for individuals with new-onset epilepsy. However,
our study included only those with new-onset epilepsy.
Unlike prior research [27], our study results did not find a
significant relationship between suicide-related behaviors
and chronic pain or high disease burden. Moreover, the
relationship between dementia and suicide-related behav-
iors was not significant after psychiatric comorbidities and
AEDs were included in the multivariable model, suggesting
that the relationship may be indirect through depressive dis-
orders for both suicide-related behaviors and dementia.
There are several limitations of the current study. First,
suicide-related behaviors were infrequent so the sample
size was small, although considerably larger than the FDA
analysis. The population studied were older adults treated
with AED monotherapy, therefore these findings may not
reflect the effects of AED in younger age groups and those
treated with polytherapy. Due to the small number of indi-
viduals prescribed levetiracetam and lamotrigine, when
analyzed individually an analysis could not generate a reli-
able odds ratio or confidence interval. Therefore the data
from these two AEDs were combined. In the future, larger
Table 2: Conditional logistic regression model predicting suicide-related behaviors: psychiatric comorbidities and 
antiepileptic drugs.
OR 95% Confidence Interval
Affective Disorders# 4.2 2.4 to 7.5
Antiepileptic Drugs (vs. Gabapentin)
Phenobarbital 0.80 0.2 to 2.6
Phenytoin 1.0 0.2 to 4.9
Carbamazepine 1.2 0.3 to 5.5
Valproate 2.3 1.0 to 5.3
Newer AEDs 10.2 1.1 to 97.0
# Depression, Anxiety, PTSD
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among various AEDs or different diagnostic groups. Sec-
ond, the administrative data may have limited our ability to
identify all cases of suicide-related behaviors. Our method
is similar to studies by Valenstein and colleagues examining
suicide-related behaviors in the VA, suggesting it is a rea-
sonable approach [28,29]. Our use of both VA and Medi-
care data would identify individuals who received care in
either VA or Medicare-reimbursed systems data, thus this
limitation would affect all individuals on AEDs, thereby
minimizing bias. Moreover, the study population consisted
of older VA patients who were almost all men and predomi-
nantly white. Thus, findings may not generalize to younger
patients or women. The racial composition of the sample
was similar to the racial composition of older Americans
[30]. Finally, because we do not have data for individuals
not exposed to AEDs we can only examine differences
among AEDs.
Conclusions
The FDA alert has the potential to significantly change the
medical management of a variety of medical conditions by
altering healthcare providers' prescribing patterns and
patient compliance. Following a review of the literature,
Hesdorffer and Kanner recently concluded that AEDs prob-
ably have little impact on the relationship between suicide-
related behaviors and epilepsy [31]. Most likely suicide-
related behaviors in individuals treated with AEDs is multi-
factorial, including disease type/severity, AED type/dose/
treatment duration and co-existing psychiatric conditions.
Our study found that in older patients with new monother-
apy AED use, the most important predictive factor of sui-
cide was a diagnosis of affective disorder prior to initiation
of AED monotherapy treatment. This is consistent with
other studies addressing suicide in the elderly. One study
estimated that 74% of late life suicides would be prevented
if affective illness were eliminated from the population
[32], illustrating the need for accurate diagnosis and treat-
ment of affective disorders in the elderly. As our study
found that prior psychiatric comorbidity was the strongest
predictor of suicide-related behaviors in our sample of older
individuals receiving new AED monotherapy, additional
research of large clinical samples of all ages is needed
before we can confirm the finding that AED exposure is
associated with suicide-related behaviors in the general
population of AED users, and not due to confounding.
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